Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:17:19.633Z.
Calculation as of: 2026-10-06T19:17:19.633Z.
Quote observation: 2026-10-06T19:10:31.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 93c5e63ae445a2e41424364838d154d4df2cbb6a4085a726ee5a5ae15b1ce67b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$60.49M
EV/Sales Ratio
N/A
TTM Avg
0.38x
3Y Avg
1.19x
5Y Avg
1.19x
Market Cap
$60.68M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$60.21M
EV/Sales Ratio
N/A
TTM Avg
236.83x
3Y Avg
178.58x
5Y Avg
259.06x
Market Cap
$60.95M
EV/Sales Ratio
N/A
TTM Avg
10156.67x
3Y Avg
5697.35x
5Y Avg
5697.35x
Market Cap
$61.95M
EV/Sales Ratio
1.25x
TTM Avg
1.74x
3Y Avg
2.85x
5Y Avg
4.03x
Market Cap
$58.75M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $60.46M | N/A | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.49M | N/A | 0.38x | 1.19x | 1.19x |
| PDS Biotechnology Corporation (PDSB)vs › | $60.68M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.21M | N/A | 236.83x | 178.58x | 259.06x |
| Fractyl Health, Inc. (GUTS)vs › | $60.95M | N/A | 10156.67x | 5697.35x | 5697.35x |
| Adicet Bio, Inc. (ACET)vs › | $59.01M | N/A | 8.16x | 93.50x | 96.95x |
| Heron Therapeutics, Inc. (HRTX)vs › | $61.95M | 1.25x | 1.74x | 2.85x | 4.03x |
| Connect Biopharma Holdings Limited (CNTB)vs › | $58.75M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.54M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $58.21M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
